Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sacituzumab tirumotecan + bevacizumab in previously treated advanced gastric/GEJ adenocarcinoma
ChiCTR2500108816Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Objective Response Rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500108816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108816.